Oral Manifestations of Inflammatory Bowel Disease and the Role of Non-Invasive Surrogate Markers of Disease Activity
Inflammatory bowel disease (IBD), which includes Crohn’s disease (CD) and ulcerative colitis (UC), can be associated with several extra-intestinal manifestations requiring a multidisciplinary management both in terms of work-up and therapy. Oral lesions are common in patients with IBD, with a preval...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-06-01
|
| Series: | Medicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2305-6320/7/6/33 |
| _version_ | 1797565160960819200 |
|---|---|
| author | Davide Giuseppe Ribaldone Selvaggia Brigo Michela Mangia Giorgio Maria Saracco Marco Astegiano Rinaldo Pellicano |
| author_facet | Davide Giuseppe Ribaldone Selvaggia Brigo Michela Mangia Giorgio Maria Saracco Marco Astegiano Rinaldo Pellicano |
| author_sort | Davide Giuseppe Ribaldone |
| collection | DOAJ |
| description | Inflammatory bowel disease (IBD), which includes Crohn’s disease (CD) and ulcerative colitis (UC), can be associated with several extra-intestinal manifestations requiring a multidisciplinary management both in terms of work-up and therapy. Oral lesions are common in patients with IBD, with a prevalence ranging from 5% to 50%. These can represent an oral location of IBD as well as a side-effect of drugs used to treat the intestinal disease. Oral manifestations, occurring in patients with IBD, can be divided in nonmalignant, specific, and non-specific ones, and malignant lesions. While there is undoubtedly a need to search for an IBD in patients with oral lesions associated with intestinal symptoms, the work-up of those with an exclusive oral lesion should be personalized. Fecal calprotectin is a non-invasive marker of intestinal inflammation and may be used to select which patients need to undergo endoscopic examination, thereby avoiding unnecessary investigations. The pharmacological armamentarium to treat oral lesions associated with IBD includes topical or systemic corticosteroids, immunosuppressive agents, and biologic drugs. |
| first_indexed | 2024-03-10T19:09:04Z |
| format | Article |
| id | doaj.art-50e4a911c9204913aff9fc7a94fc0fc8 |
| institution | Directory Open Access Journal |
| issn | 2305-6320 |
| language | English |
| last_indexed | 2024-03-10T19:09:04Z |
| publishDate | 2020-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicines |
| spelling | doaj.art-50e4a911c9204913aff9fc7a94fc0fc82023-11-20T03:58:23ZengMDPI AGMedicines2305-63202020-06-01763310.3390/medicines7060033Oral Manifestations of Inflammatory Bowel Disease and the Role of Non-Invasive Surrogate Markers of Disease ActivityDavide Giuseppe Ribaldone0Selvaggia Brigo1Michela Mangia2Giorgio Maria Saracco3Marco Astegiano4Rinaldo Pellicano5Department of Medical Sciences, University of Turin, 10126 Turin, ItalyBow Lane Dental Group, St George’s Hospital, Bupa Dental Care, London SW17 0QT, UKDepartment of Medical Sciences, University of Turin, 10126 Turin, ItalyDepartment of Medical Sciences, University of Turin, 10126 Turin, ItalyUnit of Gastroenterology, Molinette Hospital, 10126 Turin, ItalyUnit of Gastroenterology, Molinette Hospital, 10126 Turin, ItalyInflammatory bowel disease (IBD), which includes Crohn’s disease (CD) and ulcerative colitis (UC), can be associated with several extra-intestinal manifestations requiring a multidisciplinary management both in terms of work-up and therapy. Oral lesions are common in patients with IBD, with a prevalence ranging from 5% to 50%. These can represent an oral location of IBD as well as a side-effect of drugs used to treat the intestinal disease. Oral manifestations, occurring in patients with IBD, can be divided in nonmalignant, specific, and non-specific ones, and malignant lesions. While there is undoubtedly a need to search for an IBD in patients with oral lesions associated with intestinal symptoms, the work-up of those with an exclusive oral lesion should be personalized. Fecal calprotectin is a non-invasive marker of intestinal inflammation and may be used to select which patients need to undergo endoscopic examination, thereby avoiding unnecessary investigations. The pharmacological armamentarium to treat oral lesions associated with IBD includes topical or systemic corticosteroids, immunosuppressive agents, and biologic drugs.https://www.mdpi.com/2305-6320/7/6/33inflammatory bowel diseaseCrohn’s diseaseulcerative colitisextra-intestinal manifestationsorofacial granulomatosistag-like lesions |
| spellingShingle | Davide Giuseppe Ribaldone Selvaggia Brigo Michela Mangia Giorgio Maria Saracco Marco Astegiano Rinaldo Pellicano Oral Manifestations of Inflammatory Bowel Disease and the Role of Non-Invasive Surrogate Markers of Disease Activity Medicines inflammatory bowel disease Crohn’s disease ulcerative colitis extra-intestinal manifestations orofacial granulomatosis tag-like lesions |
| title | Oral Manifestations of Inflammatory Bowel Disease and the Role of Non-Invasive Surrogate Markers of Disease Activity |
| title_full | Oral Manifestations of Inflammatory Bowel Disease and the Role of Non-Invasive Surrogate Markers of Disease Activity |
| title_fullStr | Oral Manifestations of Inflammatory Bowel Disease and the Role of Non-Invasive Surrogate Markers of Disease Activity |
| title_full_unstemmed | Oral Manifestations of Inflammatory Bowel Disease and the Role of Non-Invasive Surrogate Markers of Disease Activity |
| title_short | Oral Manifestations of Inflammatory Bowel Disease and the Role of Non-Invasive Surrogate Markers of Disease Activity |
| title_sort | oral manifestations of inflammatory bowel disease and the role of non invasive surrogate markers of disease activity |
| topic | inflammatory bowel disease Crohn’s disease ulcerative colitis extra-intestinal manifestations orofacial granulomatosis tag-like lesions |
| url | https://www.mdpi.com/2305-6320/7/6/33 |
| work_keys_str_mv | AT davidegiusepperibaldone oralmanifestationsofinflammatoryboweldiseaseandtheroleofnoninvasivesurrogatemarkersofdiseaseactivity AT selvaggiabrigo oralmanifestationsofinflammatoryboweldiseaseandtheroleofnoninvasivesurrogatemarkersofdiseaseactivity AT michelamangia oralmanifestationsofinflammatoryboweldiseaseandtheroleofnoninvasivesurrogatemarkersofdiseaseactivity AT giorgiomariasaracco oralmanifestationsofinflammatoryboweldiseaseandtheroleofnoninvasivesurrogatemarkersofdiseaseactivity AT marcoastegiano oralmanifestationsofinflammatoryboweldiseaseandtheroleofnoninvasivesurrogatemarkersofdiseaseactivity AT rinaldopellicano oralmanifestationsofinflammatoryboweldiseaseandtheroleofnoninvasivesurrogatemarkersofdiseaseactivity |